Russia’s Enteromix, a personalized mRNA-based cancer vaccine, has demonstrated 100% efficacy and safety in clinical trials, offering a potential breakthrough in cancer treatment. Developed using technology similar to COVID-19 vaccines, it trains the immune system to eliminate cancer cells without serious side effects. The vaccine awaits final approval from the Ministry of Health for public availability.
In what could be a miracle improving and saving thousands of lives across the globe, Russia’s mRNA-based vaccine Enteromix has displayed 100% efficacy and safety in clinical trials. This could be a hope against fighting aggressive cancers and preventing them.”The Russian Enteromix cancer vaccine is now ready for clinical use, the Federal Medical and Biological Agency (FMBA) has announced. FMBD head Veronica Skvortsova said the mRNA-based vaccine had successfully passed preclinical trials, demonstrating its safety and high effectiveness. The vaccine showed significant results in shrinking tumors and slowing their growth, and has also been found safe for repeated use. The vaccine will be customized for each patient, tailored to their individual RNA, Skvortsova said. She added that the first form of the vaccine will be used to treat colorectal cancer, while another version is in development for glioblastoma — a brain cancer — and specific types of melanoma, a skin cancer,” Sputnik, a global wire and digital news service has posted on X
Enteromix was developed using cutting-edge technology, similar to the one used in COVID-19 vaccines.
It works by training the immune system to recognize and eliminate cancer cells. Additionally, it is personalized for every individual patient.Interestingly, unlike chemotherapy or radiation, there were no serious side effects of the vaccine and patients tolerated it well.
Earlier, it was revealed that Russia had begun clinical tria ..
